CYP19A1 and breast cancer: In a study by Ewertz and colleagues on 53,816 women with early-stage breast cancer treated with different regimens of chemotherapy or endocrine therapy (tamoxifen or aromatase inhibitors), the authors observed an increased risk of developing distant metastases in obese patients compared to lean patients [177].